MYRIAD GENETICS INC
MYGN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MYGN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MYGN
Myriad Genetics is a molecular diagnostics company focused on hereditary cancer, prenatal health, and mental health testing, leveraging a broad portfolio and commercial reach to drive growth.
Key risk: Continued GAAP net losses
BioSniper Score
Based on 5 of 6 signals
Market Cap
$302.3M
Cash Runway
60.9 moLead Asset
global liquid biopsy companion diagnostic (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial for MYRIAD GENETICS INC.
Myriad Genetics is a molecular diagnostics company focused on hereditary cancer, prenatal health, and mental health testing, leveraging a broad portfolio and commercial reach to drive growth.
- Total revenue of $190.7M and net loss of -$43.2M for the period ending 2026-06-30 [sec].
- Cash & equivalents of $116.8M, shareholders' equity of $388.1M, and total debt of $120.7M as of 2026-06-30 [sec].
- Strategy centers on three pillars: leadership in the Cancer Care Continuum, growth in Prenatal Health and Mental Health, and sustained profitable growth through operational discipline [sec · filed 2026-04-14].
- Entered a strategic collaboration with PATHOMIQ to add AI technology to its Oncology portfolio, with a first AI-driven prostate cancer test expected to launch in 2025 [sec · filed 2025-04-09].
- Named on Forbes list of America's Best Employers 2025 and achieved Great Place to Work Certification for the third consecutive year [sec · filed 2026-04-14].
What works
- Revenue has grown at a compound annual growth rate of 11.1% over the past two years, with adjusted operating income increasing by $54.6 million [sec · filed 2025-04-09].
- The company has a strong reputation for trusted high-quality tests and customer service, and an established commercial reach in community medicine [sec · filed 2026-04-14].
- Recent product launches and pipeline developments, including AI-driven tests and expanded prenatal offerings (FirstGene), position the company for growth [sec · filed 2025-04-09][sec · filed 2024-04-17].
What to weigh
- The company reported a GAAP net loss of -$43.2M for the period ending 2026-06-30, indicating ongoing unprofitability [sec].
- GAAP operating loss was $(257.4) million in fiscal year 2023, though adjusted operating loss improved to $(25.5) million [sec · filed 2024-04-17].
- The company faces the challenge of integrating new technologies (e.g., AI from PATHOMIQ) and achieving commercial success in competitive markets [sec · filed 2025-04-09].
From the filings
Quoted directly from source documents.
Revenue growth and adjusted operating income improvement over two years
“over the past two years, our revenue has increased at a compound annual growth rate of 11.1%, our adjusted operating income has increased by $54.6 million”
SEC filings · April 9, 2025
Strategic collaboration with PATHOMIQ for AI technology in oncology
“We recently entered into a strategic collaboration with PATHOMIQ to add artificial intelligence (AI) technology to our Oncology portfolio including an exclusive license of PATHOMIQ AI technology platform for prostate cancer.”
SEC filings · April 9, 2025
Company named on Forbes list of America's Best Employers 2025
“Named on the Forbes list of America's Best Employers 2025 and achieved a Great Place to Work ® Certification for the third consecutive year.”
SEC filings · April 14, 2026
Risks & what to watch (4)›
Key risks
- Continued GAAP net losses — The company reported a net loss of -$43.2M for the period ending 2026-06-30, indicating ongoing unprofitability [sec].
- Integration of new technologies — Successfully integrating AI technology from PATHOMIQ and launching new tests carries execution risk [sec · filed 2025-04-09].
- Competitive market dynamics — The molecular diagnostics market is competitive, and the company must differentiate its tests to maintain market share [sec · filed 2024-04-17].
- Debt and cash position — Total debt of $120.7M against cash of $116.8M as of 2026-06-30 may constrain financial flexibility [sec].
What to watch
- Commercial launch and adoption of the first AI-driven prostate cancer test in 2025 [sec · filed 2025-04-09].
- Progress in growing Prenatal Health and Mental Health revenues at or above market growth [sec · filed 2026-04-14].
- Ability to achieve sustained profitability and positive adjusted operating cash flow [sec · filed 2024-01-16].
- Further developments in the Cancer Care Continuum portfolio, including the Precise MRD test [sec · filed 2024-04-17].
Sources: SEC filings · SEC MD&A · Generated August 24, 2026 · How we verify sources →
Run MYRIAD GENETICS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MYRIAD GENETICS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
60.9 months
D/E 1.10 · 0% dilution
Lead: Approved
2 candidates
No upcoming catalysts tracked
2 buys · 1 sell (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
202
Total value held
$513.9M
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 125,000,000 | $122.9M |
| blackrock, inc. | 8,889,644 | $40.0M |
| vanguard capital management llc | 7,849,050 | $35.3M |
| millennium management llc | 6,668,817 | $30.0M |
| glenview capital management, llc | 5,411,978 | $24.4M |
| d. e. shaw & co., inc. | 4,499,724 | $20.2M |
| state street corp | 4,424,027 | $19.9M |
| morgan stanley | 3,168,742 | $14.3M |
| vanguard portfolio management llc | 2,582,231 | $11.6M |
| goldman sachs group inc | 2,366,092 | $10.6M |
Showing top 10 of 202 institutional holders of MYRIAD GENETICS INC. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 8.6%
- Days to cover
- 7.7
- Shares short
- 7,883,496
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MYGN short interestGovernance
Frequently asked questions
What is the AI investment thesis for MYRIAD GENETICS INC?
Myriad Genetics is a molecular diagnostics company focused on hereditary cancer, prenatal health, and mental health testing, leveraging a broad portfolio and commercial reach to drive growth.
What is MYRIAD GENETICS INC's lead drug candidate?
MYRIAD GENETICS INC's most advanced tracked candidate is global liquid biopsy companion diagnostic (Preclinical) for precision oncology.
Who is the CEO of MYRIAD GENETICS INC?
Mr. Samraat S. Raha is the chief executive officer of MYRIAD GENETICS INC (MYGN).
Where is MYRIAD GENETICS INC headquartered?
MYRIAD GENETICS INC (MYGN) is headquartered in Salt Lake City, UT, United States.
What therapeutic areas does MYRIAD GENETICS INC focus on?
MYRIAD GENETICS INC develops therapies across Oncology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.